Skip to content

Study · Randomized controlled trial · n = 61 · 2026

3 results

Reproductive hormone stability with prolonged intranasal oxytocin in adults with obesity.

Galbiati F, Hiranandani S, Wronski ML, Plessow F, Holman K, Asanza E, Smith SE, Muhammed M, Golden ER, Hadaway N, Getachew E, Misra M, Aulinas A, Lawson EA

International journal of obesity (2005)9 Apr 2026

PMID41951782 (opens in a new tab)PMCIDPMC13078695 (opens in a new tab)DOI10.1038/s41366-026-02074-7 (opens in a new tab)PepBankPUB-41951782
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In adults with obesity, eight weeks of intranasal oxytocin did not change prolactin levels differently from placebo.

    In plain wordsIn adults with obesity, eight weeks of oxytocin did not change prolactin levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeProlactin level change
    Study

    n = 61

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    24 IU four times daily · intranasal · eight weeksAs given in this study (human).

    Measurements

    P value
    ≥ 0.14
    prolactin or sex steroid levels

    Source sentences

    Summary
    Oxytocin vs. placebo groups did not differ for effects on prolactin or sex steroid levels (p's ≥ 0.140).
    2 context sentences
    Summary · context
    Main outcome measures were pre- and post-treatment fasting estradiol, testosterone, and prolactin; exploratory outcome measure was on-treatment menstrual cycle length.
    Summary · context
    Sixty-one adults with obesity (52% females) participated in a longitudinal randomized clinical trial data and received eight-weeks intranasal oxytocin (24 IU) four times daily or placebo.
  2. 02HumanRandomized controlled trialSafety outcome

    In adults with obesity, eight weeks of intranasal oxytocin did not change fasting estradiol or testosterone differently from placebo.

    In plain wordsIn adults with obesity, eight weeks of oxytocin did not change sex hormone levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSex steroid levels (estradiol and testosterone)
    Study

    n = 61

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    24 IU four times daily · intranasal · eight weeksAs given in this study (human).

    Measurements

    P value
    ≥ 0.14
    prolactin or sex steroid levels

    Source sentences

    Summary
    Oxytocin vs. placebo groups did not differ for effects on prolactin or sex steroid levels (p's ≥ 0.140).
    2 context sentences
    Summary · context
    Main outcome measures were pre- and post-treatment fasting estradiol, testosterone, and prolactin; exploratory outcome measure was on-treatment menstrual cycle length.
    Summary · context
    Sixty-one adults with obesity (52% females) participated in a longitudinal randomized clinical trial data and received eight-weeks intranasal oxytocin (24 IU) four times daily or placebo.
  3. 03HumanRandomized controlled trialSafety outcome

    In women with obesity, eight weeks of intranasal oxytocin did not change mean on-treatment menstrual cycle length compared with placebo.

    In plain wordsIn women with obesity, eight weeks of oxytocin did not change menstrual cycle length compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeOn-treatment mean menstrual cycle length
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    24 IU four times daily · intranasal · eight weeksAs given in this study (human).

    Measurements

    P value
    0.234
    menstrual cycle length

    Source sentences

    Summary
    On-treatment mean menstrual cycle length did not differ across groups (p = 0.234).
    1 context sentence
    Summary · context
    Sixty-one adults with obesity (52% females) participated in a longitudinal randomized clinical trial data and received eight-weeks intranasal oxytocin (24 IU) four times daily or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.